

Mucins as Diagnostic Biomarkers for Gastric Cancer: A Key Approach in Early Detection

Shen Keita*

Department of General Surgery, University of Seville, Seville, Spain

Commentary

Received: 27-Dec-2024, Manuscript No. MCO-24-156756; **Editor assigned:** 01-Jan-2025, PreQC No. MCO-24-156756 (PQ); **Reviewed:** 15-Jan-2025, QC No. MCO-24-156756; **Revised:** 07-Mar-2025, Manuscript No. MCO-24-156756 (R); **Published:** 14-Mar-2025, DOI: 10.4172/medclinoncol.9.01.003.

***For Correspondence:**

Shen Keita, Department of General Surgery, University of Seville, Seville, Spain, **E-mail:**

keita.891shen@163.edu.com

Citation: Keita S. Mucins as Diagnostic Biomarkers for Gastric Cancer: A Key Approach in Early Detection. Med Clin Oncol. 2025;09:003.

Copyright: © 2025 Keita S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

DESCRIPTION

Gastric cancer, one of the leading causes of cancer-related deaths worldwide, is often diagnosed at advanced stages, limiting the effectiveness of treatment options. Early detection remains the cornerstone for improving survival rates, but current diagnostic tools, such as endoscopy and biopsy, are invasive, costly, and not always reliable in detecting early-stage cancer. In recent years, mucins glycoproteins expressed on the surface of epithelial cells have emerged as promising diagnostic biomarkers for gastric cancer. Their potential to aid in the early detection, diagnosis, and prognosis of gastric cancer could significantly improve patient outcomes and pave the way for less invasive diagnostic approaches.

Mucins are large glycoproteins that play a crucial role in protecting and lubricating the epithelial surface, including that of the gastrointestinal tract. In healthy individuals, mucins are secreted by normal epithelial cells to form a protective mucus layer, shielding underlying tissues from mechanical damage, pathogens, and chemical irritants. However, in the context of cancer, mucin expression is often altered, leading to changes in their structure, quantity, and distribution. This dysregulation in mucin expression is particularly evident in gastric cancer, where certain mucins are overexpressed or aberrantly localized, making them potential biomarkers for the disease.

Research & Reviews: Medical and Clinical Oncology

The most well-known mucins associated with gastric cancer are MUC1, MUC5AC, and MUC6. MUC1, in particular, has been widely studied due to its overexpression in various cancer types, including gastric cancer. This transmembrane mucin is often found on the surface of tumor cells, where it contributes to tumor progression by promoting cell adhesion, invasion, and immune evasion. Studies have shown that elevated levels of MUC1 in serum or gastric tissue can serve as an early indicator of gastric cancer. Additionally, MUC5AC and MUC6 are secreted mucins that have been found to be overexpressed in gastric cancer tissues, particularly in the presence of mucinous adenocarcinomas. These mucins are not typically expressed in normal gastric tissue, making them highly specific markers for gastric cancer.

The detection of mucins as biomarkers for gastric cancer offers several advantages over traditional diagnostic methods. First, mucins can be detected in various biological fluids, including serum, saliva, and gastric juice, making them non-invasive and easily accessible for patients. Liquid biopsy, a technique that analyzes circulating tumor markers in blood or other bodily fluids, is becoming an increasingly popular method for cancer diagnosis and monitoring. By detecting elevated levels of specific mucins in these fluids, it is possible to identify gastric cancer at an early stage, even before symptoms manifest. This early detection can provide a window for intervention, improving the chances of successful treatment and survival.

Furthermore, mucin-based biomarkers could help in distinguishing gastric cancer from other gastrointestinal diseases that share similar symptoms, such as peptic ulcers or gastritis. In many cases, these conditions are difficult to differentiate from gastric cancer using conventional diagnostic methods, leading to delays in treatment. The use of mucins as diagnostic markers could provide a more accurate and reliable method for early detection, potentially reducing unnecessary procedures and enhancing patient care.

CONCLUSION

Mucins represent a promising class of diagnostic biomarkers for gastric cancer. Their overexpression in gastric cancer tissues and their presence in easily accessible bodily fluids make them ideal candidates for non-invasive early detection methods. Although challenges remain, particularly regarding the variability of mucin expression and the need for more robust clinical validation, the potential of mucins to improve the early diagnosis and prognosis of gastric cancer is undeniable. Continued research and technological advancements in biomarker detection will likely pave the way for mucin-based diagnostic tests to become an integral part of clinical oncology, offering patients a better chance for early intervention and improved outcomes.